Work

Mild cognitive impairement in patients with type 2 diabetes mellitus and metabolic syndrome

Year: 2026

Type: article

Abstract: Objective. This study aims to evaluate the effect of Thiocetam on cognitive function in patients with type 2 diabetes mellitus in real-world clinical practice. Material and methods. The TIOKON observational, non-interventional, comparative study of Thiocetam in patients with type 2 diabetes mellitus and cognitive impairment in real-world clinical practice included 438 patients with type 2 diabetes mellitus, metabolic syndrome, and mild cognitive impairment. Group 1 patients (n = 133) received standard therapy alone for type 2 diabetes mellitus and comorbidities; Group 2 patients (n = 147) received therapy incorporating of a drug containing piracetam and thiotriazoline into the treatment regimen (intramuscularly for 2 weeks, followed by 2 tablets 3 times daily for 6 weeks); Group 3 patients (n = 158) received Thiocetam (2 tablets 3 times daily) for 8 weeks. The nature of complaints, cognitive functions, carbohydrate and lipid metabolism parameters, and the occurrence of adverse events were assessed. Results. During treatment, patients in Groups 2 and 3 exhibited improvements in memory, concentration, and cognitive performance. Subjective improvement, manifested as a reduction in the number and severity of complaints, occurred earlier in Group 2 patients (upon completion of the intramuscular injection course). MoCA scores increased from 22.3 ± 1.9 to 27.5 ± 0.9 in Group 2 (p < 0.05) and to 27.9 ± 0.8 in Group 3 (p < 0.05). Statistically significant differences compared to baseline and Group 1 were observed in Groups 2 and 3 at Visit 3 (with no significant differences found between Groups 2 and 3). By the end of the follow-up period, levels of glycated hemoglobin (p < 0.05), capillary blood glucose (p < 0.05), and low-density lipoprotein cholesterol (p < 0.05) had significantly decreased. An earlier onset of effect was observed in patients who underwent intramuscular therapy. Regardless of the route of administration, no serious adverse events occurred. The majority of Group 2 patients rated the treatment outcomes as good or very good. Conclusion. The drug has demonstrated efficacy and safety in patients with type 2 diabetes mellitus, metabolic syndrome, and mild cognitive impairment and can be widely utilised for the management of this patient population.

Source: Лечащий врач

DOI: 10.51793/os.2026.29.8.005